Replies to post #441450 on NorthWest Biotherapeutics Inc (NWBO)

[jondoeuk]

At the recommended Phase 2 dose of lenzilumab (plus Yescarta), the ORR was 100% and no patient experienced Gr3 (or above) cytokine release syndrome or neurotoxicity. A randomised, multicenter, potentially registrational, PhII trial (n=150) should be underway soon.

Going forward, they may not even need to give that mAb (as they can knockout GM-CSF in the CAR-T cells) https://ashpublications.org/blood/article/133/7/697/260575/GM-CSF-inhibition-reduces-cytokine-release